Literature DB >> 10694214

Effects of nicotine and chlorisondamine on cerebral glucose utilization in immobilized and freely-moving rats.

T Marenco1, S Bernstein, P Cumming, P B Clarke.   

Abstract

Chlorisondamine blocks central nicotinic receptors for many weeks via an unknown mechanism. Intracerebroventricular administration of [(3)H]-chlorisondamine in rats results in an anatomically restricted and persistent intracellular accumulation of radioactivity. The initial aim of the present study was to test whether nicotinic receptor antagonism by chlorisondamine is also anatomically restricted. Male adult rats were pretreated several times with nicotine to avoid the disruptive effects of the drug seen in drug-naïve animals. They then received chlorisondamine (10 microg i. c.v.) or saline, and local cerebral glucose utilization (LCGU) was measured 4 weeks later after acute nicotine (0.4 mg kg(-1) s.c.) or saline administration. During testing, rats were partially immobilized. Nicotine significantly increased LCGU in the anteroventral thalamus and in superior colliculus. Chlorisondamine completely blocked the first of these effects. Chlorisondamine significantly reduced LCGU in the lateral habenula, substantia nigra pars compacta, ventral tegmental area, and cerebellar granular layer. The second experiment was of similar design, but the rats were not pre-exposed to nicotine, and were tested whilst freely-moving. Acute nicotine significantly increased LCGU in anteroventral thalamus, superior colliculus, medial habenula and dorsal lateral geniculate. Overall, however, nicotine significantly decreased LCGU. Most or all of the central effects of nicotine on LCGU were reversed by chlorisondamine given 4 weeks beforehand. These findings suggest that chlorisondamine blocks nicotinic effects widely within the brain. They also indicate that in freely-moving rats, nicotine can reduce or stimulate cerebral glucose utilization, depending on the brain area. British Journal of Pharmacology (2000) 129, 147 - 155

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10694214      PMCID: PMC1621125          DOI: 10.1038/sj.bjp.0703005

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  46 in total

1.  A new orally active quaternary ammonium, ganglion blocking drug capable of reducing blood pressure, Su-3088.

Authors:  K S GRIMSON; A K TARAZI; J W FRAZER
Journal:  Circulation       Date:  1955-05       Impact factor: 29.690

2.  Immunohistochemical localization of neuronal nicotinic receptors in the rodent central nervous system.

Authors:  L W Swanson; D M Simmons; P J Whiting; J Lindstrom
Journal:  J Neurosci       Date:  1987-10       Impact factor: 6.167

3.  Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.

Authors:  F E Pontieri; G Tanda; F Orzi; G Di Chiara
Journal:  Nature       Date:  1996-07-18       Impact factor: 49.962

Review 4.  Nicotinic receptors in mammalian brain: localization and relation to cholinergic innervation.

Authors:  P B Clarke
Journal:  Prog Brain Res       Date:  1993       Impact factor: 2.453

5.  Conditioned aversion after delay place conditioning with nicotine.

Authors:  P J Fudala; E T Iwamoto
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  Reduced antinociception in mice lacking neuronal nicotinic receptor subunits.

Authors:  L M Marubio; M del Mar Arroyo-Jimenez; M Cordero-Erausquin; C Léna; N Le Novère; A de Kerchove d'Exaerde; M Huchet; M I Damaj; J P Changeux
Journal:  Nature       Date:  1999-04-29       Impact factor: 49.962

7.  Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test.

Authors:  J D Brioni; A B O'Neill; D J Kim; M W Decker
Journal:  Eur J Pharmacol       Date:  1993-07-06       Impact factor: 4.432

8.  [3H]nicotine binding sites are associated with mammalian optic nerve terminals.

Authors:  G T Prusky; M S Cynader
Journal:  Vis Neurosci       Date:  1988       Impact factor: 3.241

9.  Chlorisondamine blocks acquisition of the conditioned taste aversion produced by (-)-nicotine.

Authors:  C Reavill; I P Stolerman; R Kumar; H S Garcha
Journal:  Neuropharmacology       Date:  1986-09       Impact factor: 5.250

10.  Intraperitoneal administration and other modifications of the 2-deoxy-D-glucose technique.

Authors:  R C Meibach; S D Glick; D A Ross; R D Cox; S Maayani
Journal:  Brain Res       Date:  1980-08-11       Impact factor: 3.252

View more
  10 in total

1.  Brain activation by short-term nicotine exposure in anesthetized wild-type and beta2-nicotinic receptors knockout mice: a BOLD fMRI study.

Authors:  S V Suarez; A Amadon; E Giacomini; A Wiklund; J-P Changeux; D Le Bihan; S Granon
Journal:  Psychopharmacology (Berl)       Date:  2008-09-26       Impact factor: 4.530

2.  Regional metabolite levels and turnover in the awake rat brain under the influence of nicotine.

Authors:  Jie Wang; Lihong Jiang; Yifeng Jiang; Xiaoxian Ma; Golam M I Chowdhury; Graeme F Mason
Journal:  J Neurochem       Date:  2010-03-14       Impact factor: 5.372

3.  Smoking normalizes cerebral blood flow and oxygen consumption after 12-hour abstention.

Authors:  Manouchehr S Vafaee; Albert Gjedde; Nasrin Imamirad; Kim Vang; Mallar M Chakravarty; Jason P Lerch; Paul Cumming
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-31       Impact factor: 6.200

4.  Nicotine and electronic cigarette (E-Cig) exposure decreases brain glucose utilization in ischemic stroke.

Authors:  Ali E Sifat; Bhuvaneshwar Vaidya; Mohammad A Kaisar; Luca Cucullo; Thomas J Abbruscato
Journal:  J Neurochem       Date:  2018-10-18       Impact factor: 5.372

5.  Multimodal Neuroimaging Differences in Nicotine Abstinent Smokers Versus Satiated Smokers.

Authors:  Bader Chaarani; Philip A Spechler; Alexandra Ivanciu; Mitchell Snowe; Joshua P Nickerson; Stephen T Higgins; Hugh Garavan
Journal:  Nicotine Tob Res       Date:  2019-05-21       Impact factor: 4.244

Review 6.  Functional brain imaging of tobacco use and dependence.

Authors:  Arthur L Brody
Journal:  J Psychiatr Res       Date:  2005-06-24       Impact factor: 4.791

Review 7.  Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.

Authors:  G W Ross; H Petrovitch
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 8.  In vivo brain imaging of human exposure to nicotine and tobacco.

Authors:  Anil Sharma; Arthur L Brody
Journal:  Handb Exp Pharmacol       Date:  2009

Review 9.  Brain Energy Metabolism in Ischemic Stroke: Effects of Smoking and Diabetes.

Authors:  Ali Ehsan Sifat; Saeideh Nozohouri; Sabrina Rahman Archie; Ekram Ahmed Chowdhury; Thomas J Abbruscato
Journal:  Int J Mol Sci       Date:  2022-07-31       Impact factor: 6.208

10.  Glutamatergic and GABAergic metabolism in mouse brain under chronic nicotine exposure: implications for addiction.

Authors:  Mohammad Shameem; Anant Bahadur Patel
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.